오가피로부터 분리된 조다당 분획물의 면역자극활성 및 Cisplatin과의 병용에 의한 항암 상승작용의 유도

Immunostimulation Activity of the Crude Polysaccharides Fractionated from Eleutherococcus senticosus, and its Application to Prevent of Tumors by Combination Therapy with Cisplatin

In order to study the clinical usefulness of crude polysaccharides fractionated from Eleutherococcus senticosus, EN-3, in eliminating tumors, we have investigated the effect of combination therapy on the murine tumor metastasis and growth models. In experimental metastasis of colon26-M3.1 cells, prophylactic intravenous (I.v.) administration of EN-3 (0.5, 5, and 50 μg/mouse) inhibited tumor metastasis compared with tumor control group in 33.6, 66.8, and 81.8% respectively, The administration of EN-3 (50 μg/mouse) also exhibited a 66.1% therapeutic effect on lung tumor metastasis. Although EN-3 induced no toxic effect on both tumor cell and normal splenocyte in the concentration below 100 μg/ml in in vitro, it induced significant proliferating activity on normal splenocyte in the concentration- dependent manner, In an analysis of NK-cell activity, I.v. adminisuation of EN-3 (4~100 μg/mouse) significantly augmented NK cytotoxicity to YAC-1 tumor cells. The combination treatments of cisplatin (10 μg) and EN-3 (5 μg) induced synergistic effect on the inhibition of tumor metastasis in experimental tumor metastasis model produced by colon26-M3.1 cells. In addition, the combination treatments also exhibited prolongation of lifespan in S-180 tumor bearing mouse for over the 60 days. Even though cisplatin (2.5 μg/ml) exhibited cytotoxicity to tumor cells and inhibited tumor growth over 95% in in vitro, combination treatment with EN-3 (20 μg/ml) was induced splenocyte proliferation and produced cytokines, such as TNF- α, IL-1 and IL-12, from the macmphages. These results suggested that EN-3 stimulate immune system non-specifically and apply to the biological response modifiers (BRM) in chemoimmunotherapy for tumor prevention.